Beam Therapeutics investor relations material

Beam Therapeutics Inc. operates as a clinical-stage biotechnology company, which develops base editing technology to treat serious diseases by making precise changes to DNA and RNA. Its portfolio includes target genes that cover oncology, hematology, ophthalmology, liver disease and neurology conditions. The company was founded by David Nelles, Matthew Porteus and Feng Zhang on April 10, 2018 and is headquartered in Cambridge, MA.